FDA grants priority review to omalizumab in treatment of food allergy

Source: Healio

The FDA has accepted a supplemental biologics application for the use of omalizumab to reduce allergic reactions due to accidental exposure in patients aged 1 year and older with at least one food allergy, according to a press release.

Read More